NCT01108458View on ClinicalTrials.gov

A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

March 31, 2011

Conditions
Pancreatic Cancer
Interventions
DRUG

Pertuzumab

iv, 840 mg, 420 mg

DRUG

Erlotinib

PO, 150 mg

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

George Albert Fisher

OTHER